Browse > Article

A Comparative Study of Production of [68Ga]PSMA-11 with or without Cassette Type Modules  

Hyun-Sik, Park (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Byeong-Min, Jo (BIK THERAPEUTICS Inc.)
Hyun-Ho, An (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Hong-Jin, Lee (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Jin-Hyeong, Lee (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Gyeong-Jae, Lee (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Byung-Chul, Lee (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Won-Woo, Lee (Department of Nuclear Medicine, Seoul National University Bundang Hospital)
Publication Information
The Korean Journal of Nuclear Medicine Technology / v.26, no.2, 2022 , pp. 15-19 More about this Journal
Abstract
Purpose [68Ga]PSMA-11 is needed the high reproducibility, excellent radiochemical yield and purity. In term of radiation safety, the radiation exposure of operator for its production also should be considered. In this work, we performed a comparative study for the fully automated synthesis of [68Ga]PSMA-11 between non-cassette type and cassette type. Materials and Methods Two different type of modules (TRACERlab FX N pro for non-cassette type and BIKBox for cassette type) were used for the automated production of [68Ga]PSMA-11. According to the previously identified elution profile, Only 2.5 ml with high radioactivity was used for the reaction. After adjusting the pH of the reaction solution with HEPES buffer solution, the precursor was added and reacted with at 95 ℃ for 15 minutes. The reaction mixture was separated and purified using a C18 light cartridge. The product was eluted with 50% EtOH/saline solution and diluted with saline. It was completed by sterilizing filter. In the non-cassette type, the aforementioned process must be prepared directly. However, in the cassette method, synthesis was possible simply by installing a kit that was already completed. Results Both total [68Ga]PSMA-11 production time were 25±3(non-cassette type) and 23±3 minutes(cassette type). The radiochemical yield of the non-cassette type(65.5±5.7%) was higher than that of the cassette type(61.6±4.8%) after sterilization filter. The non-cassette type took about 120 minutes of preparation time before synthesis due to washing of synthesizer and reagent preparation. However, since the cassette type does not require washing and reagent preparation, it took about 20 minutes to prepare before synthesis. Both type of synthesizer had a radiochemical high purity(>99%). Conclusion The non-cassette type production of [68Ga]PSMA-11 showed higher radiochemical yield and lower cost than the cassette type. However, The cassette type has an advantage in terms of preparation time, convenience, and equipment maintenance.
Keywords
[$^{68}Ga$]PSMA-11; Automated synthesis; $^{68}Ge/^{68}Ga$ generator;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Park HS, Lee HJ, An HH, Moon BS, Lee BC, Lee WW, et al. Fully automated radiosynthesis of [68Ga]edotreotide ([68Ga]DOTA-TOC) and its quality controls. J Radiopharm Mol Prob 2017;3(2):85-90   DOI
2 Michael M, Yury S, Elisabath E. Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging - A Lot to Consier. Intechopen Web site. Available at: http://www.intechopen.com/chapters/70578. Published December 23, 2019.
3 Ukihide T. Prostate-specific membrane antigen(PSMA)- ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Japanese Journal of Clinical Oncology, 2020;50(4):349-356   DOI
4 Wolfgang PF, Jeremie C, Matthias E, Robert RF, Ashley M, Felix YF, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856-863   DOI
5 Michael SH, Nathan L, Roslyn JF, Colin T, Ian V, Paul T, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395:1208-16   DOI